Meanwhile, a real-world study retrospectively analyzed the association between the mutation of DNA repair-related genes and the efficacy of CDK 4/6 inhibitor plus ET in patients with HR+/HER2- advanced BC. The gene discussed is ERBB2; the disease is breast cancer.